false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
PCSK-9 Inhibitors: Basic Biology to Clinical Outco ...
PCSK-9 Inhibitors: Basic Biology to Clinical Outco ...
PCSK-9 Inhibitors: Basic Biology to Clinical Outcomes
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video is a presentation by Connie Newman, an endocrinologist, on PCSK9 inhibitors and their role in cholesterol management. PCSK9 inhibitors are a class of drugs that work by reducing the LDL cholesterol in the body. Connie discusses the different options for LDL reduction, including statins, ezetimibe, and PCSK9 inhibitors. She explains that PCSK9 inhibitors can be added to statin therapy to further reduce LDL cholesterol levels. She also discusses the benefits and safety of PCSK9 inhibitors, as well as their cost and coverage considerations. Connie presents case studies to illustrate the use of PCSK9 inhibitors in clinical practice, including considerations for different patient populations, such as those with familial hypercholesterolemia. She concludes by summarizing the key points of her presentation and expressing gratitude to her colleagues and family.
Keywords
Connie Newman
endocrinologist
PCSK9 inhibitors
cholesterol management
LDL cholesterol
statins
ezetimibe
LDL reduction
×